Cellular immunotherapy using dendritic cells against multiple myeloma

다국어 초록 (Multilingual Abstract)

Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic tool to treat multiple myeloma (MM). DC-based idiotype vaccination was recently suggested to induce idiotype-specific immune responses in MM patients. However, the clinical results so far have been largely disappointing, and the clinical effectiveness of such vaccinations in MM still needs to be demonstrated. DC-based therapies against MM may need to be boosted with other sources of tumor-associated antigens, and potent DCs should be recruited to increase the effectiveness of treatment. DCs with both high migratory capacity and high cytokine production are very important for effective DC-based cancer vaccination in order to induce high numbers of Th1-type CD4+ T cells and CD8+ cytotoxic T lymphocytes. The tumor microenvironment is also important in the regulation of tumor cell growth, proliferation, and the development of therapeutic resistance after treatment. In this review, we discuss how the efficacy of DC vaccination in MM can be improved. In addition, novel treatment strategies that target not only myeloma cells but also the tumor microenvironment are urgently needed to improve treatment outcomes.

참고문헌 (Reference)

1 Maecker B, "Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma" 121 : 842-848, 2003

2 Rosenblatt J, "Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma" 117 : 393-402, 2011

3 Hsu FJ, "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells" 2 : 52-58, 1996

4 Titzer S, "Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects" 108 : 805-816, 2000

5 Nestle FO, "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells" 4 : 328-332, 1998

6 이제중, "Ursolic acid isolated from Uncaria rhynchophylla activates human dendritic cells via TLR2 and/or TLR4 and induces the production of IFN-γ by CD4+ na？ve T cells" ELSEVIER SCIENCE BV 643 (643): 297-303, 201009

7 Bae WK, "Uncarinic acid C plus IFN-g generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate" 266 : 104-110, 2010

8 Giermasz AS, "Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines" 58 : 1329-1336, 2009

9 Nguyen-Pham TN, "Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists" 8 : 341-347, 2011

10 이제중, "Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia" FEDERATION AMER SOC EXP BIOL 84 (84): 319-325, 200807

11 Li Y, "Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells" 96 : 2828-2833, 2000

12 Wen YJ, "Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy" 99 : 3280-3285, 2002

13 Kwak LW, "Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor" 345 : 1016-1020, 1995

14 Vonderheide RH, "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes" 10 : 673-679, 1999

15 Attal M, "The role of high-dose therapy with autologous stem cell support in the era of novel agents" 46 : 127-132, 2009

16 Ridgway D, "The first 1000 dendritic cell vaccinees" 21 : 873-886, 2003

17 Brossart P, "The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes" 61 : 6846-6850, 2001

18 Yang DH, "The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma" PERGAMON-ELSEVIER SCIENCE LTD 33 (33): 665-670, 2009

19 Galustian C, "The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells" 58 : 1033-1045, 2009

20 Nefedova Y, "Targeting of Jak/STAT pathway in antigen presenting cells in cancer" 7 : 71-77, 2007

21 Qian J, "Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma- specific CTLs using dendritic cells pulsed with tumor-derived gp96" 11 : 8808-8815, 2005

22 Yang DH, "Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins" 90 : 1419-1426, 2011

23 Chiriva-Internati M, "Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma" 100 : 961-965, 2002

24 Madan RA, "Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer" 10 : 141-150, 2011

25 Liu JY, "Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine" 56 : 1597-1604, 2007

26 Napolitani G, "Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells" 6 : 769-776, 2005

27 Faure-André G, "Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain" 322 : 1705-1710, 2008

28 Gerosa F, "Reciprocal activating interaction between natural killer cells and dendritic cells" 195 : 327-333, 2002

29 Batchu RB, "Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma" 65 : 10041-10049, 2005

30 Scandella E, "Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells" 100 : 1354-1361, 2002

31 Kalinski P, "Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer" 97 : 3466-3469, 2001

32 Jonuleit H, "Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions" 27 : 3135-3142, 1997

33 Wesa A, "Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro" 30 : 75-82, 2007

34 홍성열, "Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells" AMER SOC HEMATOLOGY 108 (108): 4071-4077, 200612

35 Yi Q, "Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients" 150 : 554-564, 2010

36 Yi Q, "Optimizing dendritic cell-based immunotherapy in multiple myeloma" 117 : 297-305, 2002

37 Szmania S, "NY-ESO-1 immunotherapy for multiple myeloma" 47 : 2037-2048, 2006

38 홍성열, "Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma" AMER SOC HEMATOLOGY 114 (114): 3880-3889, 200910

39 Ostrand-Rosenberg S, "Myeloid-derived suppressor cells: linking inflammation and cancer" 182 : 4499-4506, 2009

40 Kyle RA, "Multiple myeloma" 351 : 1860-1873, 2004

41 Bergenbrant S, "Modulation of anti- idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients" 92 : 840-846, 1996

42 Quach H, "Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma" 24 : 22-32, 2010

43 de Vries IJ, "Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients" 9 : 5091-5100, 2003

44 Nguyen-Pham TN, "Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma" 35 : 1241-1247, 2011

45 Milazzo C, "Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA" 101 : 977-982, 2003

46 Lee JJ, "Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates" HARWOOD ACAD PUBL GMBH 48 (48): 2022-2031, 2007

47 Röllig C, "Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells" 34 : 100-106, 2011

48 Okada H, "Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma" 29 : 330-336, 2011

49 Brimnes MK, "Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma" 72 : 540-547, 2010

50 Harrison SJ, "Immunotherapy of multiple myeloma: the start of a long and tortuous journey" 6 : 1769-1785, 2006

51 Okada N, "Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12" 12 : 72-83, 2005

52 Ramsay AG, "Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug" 94 : 1198-1202, 2009

53 Lim SH, "Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma" 83 : 215-222, 1999

54 Wen YJ, "Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells" 97 : 1750-1755, 2001

55 Lacy MQ, "Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival" 84 : 799-802, 2009

56 Liso A, "Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma" 6 : 621-627, 2000

57 Reichardt VL, "Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells" 88 : 1139-1149, 2003

58 Kitamura H, "IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells" 23 : 491-502, 2005

59 Ogawara H, "High Th1/Th2 ratio in patients with multiple myeloma" 29 : 135-140, 2005

60 Tricot G, "Graft-versus-myeloma effect: proof of principle" 87 : 1196-1198, 1996

61 Ocadlikova D, "Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies" 57 : 455-464, 2010

62 Cull G, "Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma" 107 : 648-655, 1999

63 Vasir B, "Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation" 129 : 687-700, 2005

64 Banerjee DK, "Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients" 108 : 2655-2661, 2006

65 Hayashi T, "Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes" 102 : 1435-1442, 2003

66 Thanh Nhan Nguyen Pham, "Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist" 생화학분자생물학회 42 (42): 407-419, 2010

67 Hao S, "Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells" 26 : 300-306, 2004

68 Prabhala RH, "Dysfunctional T regulatory cells in multiple myeloma" 107 : 301-304, 2006

69 홍성열, "Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma" AMER SOC HEMATOLOGY 110 (110): 1587-1594, 200709

70 Mailliard RB, "Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function" 171 : 2366-2373, 2003

71 Brown RD, "Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor- beta1 and interleukin-10" 98 : 2992-2998, 2001

72 Yamazaki S, "Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity" 212 : 314-329, 2006

73 Butch AW, "Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein" 29 : 85-92, 2001

74 Banchereau J, "Dendritic cells as therapeutic vaccines against cancer" 5 : 296-306, 2005

75 Ratta M, "Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6" 100 : 230-237, 2002

76 Banchereau J, "Dendritic cells and the control of immunity" 392 : 245-252, 1998

77 Reid DC, "Dendritic cells and immunotherapy for malignant disease" 112 : 874-887, 2001

78 Yu H, "Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment" 7 : 41-51, 2007

79 Bendandi M, "Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation" 47 : 29-37, 2006

80 Perez-Simón JA, "Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation" 121 : 104-108, 2003

81 Kim R, "Cancer immunoediting from immune surveillance to immune escape" 121 : 1-14, 2007

82 Frasca L, "CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells" 107 : 2392-2399, 2006

83 Jarahian M, "Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells" 120 : 2625-2634, 2007

84 Mailliard RB, "Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity" 64 : 5934-5937, 2004

85 Yang DH, "Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells" SPRINGER 89 (89): 795-801, 2010

86 Höltl L, "Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide" 54 : 663-670, 2005

87 Muthuswamy R, "Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation" 68 : 5972-5978, 2008

88 Dhodapkar MV, "A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma" 197 : 1667-1676, 2003

89 Savill J, "A blast from the past: clearance of apoptotic cells regulates immune responses" 2 : 965-975, 2002